Document is current
Any future updates will be listed below
-
Authors
Castroviejo‐Bermejo, Marta
Cruz, Cristina
Llop‐Guevara, Alba
Gutiérrez‐Enríquez, Sara
Ducy, Mandy
Ibrahim, Yasir Hussein
Gris‐Oliver, Albert
Pellegrino, Benedetta
Bruna, Alejandra
Guzmán, Marta
Rodríguez, Olga
Grueso, Judit
Bonache, Sandra
Moles‐Fernández, Alejandro
Villacampa, Guillermo
Viaplana, Cristina
Gómez, Patricia
Vidal, Maria
Peg, Vicente
Serres‐Créixams, Xavier
Dellaire, Graham
Simard, Jacques
Nuciforo, Paolo
Rubio, Isabel T
Dienstmann, Rodrigo
Barrett, J Carl
Caldas, Carlos
Baselga, José
Saura, Cristina
Cortés, Javier
Déas, Olivier
Jonkers, Jos https://orcid.org/0000-0002-9264-9792
Masson, Jean‐Yves
Cairo, Stefano
Judde, Jean‐Gabriel
O'Connor, Mark J
Díez, Orland
Balmaña, Judith https://orcid.org/0000-0002-0762-6415
Serra, Violeta https://orcid.org/0000-0001-6620-1065
-
Funding
Funding for this research was provided by:
MINECO | Instituto de Salud Carlos III (FIS PI17/01080)
Programme de soutien à des initiatives internationales de recherche et d'innovation (SIIRI) du Ministère de l'Économie, de l'Innovation et des Exportations du Québec (PSR‐SIIRI‐949)
Junta Provincial de Barcelona, Asociación Española Contra el Cancer
Fundación Científica Asociación Española Contra el Cáncer (AIOC15152806CRUZ)
Fundación Científica Asociación Española Contra el Cáncer (LABAE16020PORTT)
Departamento de Salut, Generalitat de Catalunya, PERIS (SLT002/16/00477)
Miguel Servet Program (CP14/00228)
Miguel Servet Program (CP16/00034)
MINECO | Instituto de Salud Carlos III (FIS PI12‐02606)
MINECO | Instituto de Salud Carlos III (FIS PI12/02585)
MINECO | Instituto de Salud Carlos III (PI15‐00355)
MINECO | Instituto de Salud Carlos III (FIS PI13/01711)
MINECO | Instituto de Salud Carlos III (PI16/01218)
TRANSCAN‐2 (AC15/00063)
Government of Catalonia | Agència de Gestió d'Ajuts Universitaris i de Recerca (2017 SGR 540)
Canadian HIV Trials Network, Canadian Institutes of Health Research (FND‐388879)
- License Information
-
More Information
Article History
Received: 4 April 2018
Revised: 19 September 2018
Accepted: 25 September 2018
First Online: 30 October 2018
Conflict of interest
: V.S. declares a non‐commercial research agreement with AstraZeneca and Tesaro. J.B.l. is an advisory board member for Clovis, Tesaro, and Medivation and has received speaker bureau honoraria by AstraZeneca. J.C.B. and M.J.O. are employees of AstraZeneca. S.C. and J.‐G.J. are employees of XenTech. CCa is on the External Science Panel of AstraZeneca. JBas is on the Board of Directors of Foghorn and is a past board member of Varian Medical Systems, Bristol‐Myers Squibb, Grail, Aura Biosciences and Infinity Pharmaceuticals. He has performed consulting and/or advisory work for Grail, PMV Pharma, ApoGen, Juno, Lilly, Seragon, Novartis and Northern Biologics. He has stock or other ownership interests in PMV Pharma, Grail, Juno, Varian, Foghorn, Aura, Infinity, ApoGen, as well as Tango and Venthera, for which is a co‐founder. He has previously received Honoraria or Travel Expenses from Roche, Novartis, and Lilly. No potential conflict of interests were disclosed by the other authors.
